ArticleJTO clinical and research reports2026

RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC.

Pedro de Marchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.